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Abstract
Background: Anticholinergic drugs put elderly patients at a higher risk for falls, cognitive decline, and delirium
as well as peripheral adverse reactions like dry mouth or constipation. Prescribers are often unaware of the drug-
based anticholinergic burden (ACB) of their patients. This study aimed to develop an anticholinergic burden score for
drugs licensed in Germany to be used by clinicians at prescribing level.
Methods: A systematic literature search in pubmed assessed previously published ACB tools. Quantitative grading
scores were extracted, reduced to drugs available in Germany, and reevaluated by expert discussion. Drugs were
scored as having no, weak, moderate, or strong anticholinergic effects. Further drugs were identified in clinical routine
and included as well.
Results: The literature search identified 692 different drugs, with 548 drugs available in Germany. After exclusion of
drugs due to no systemic effect or scoring of drug combinations (n = 67) and evaluation of 26 additional identified
drugs in clinical routine, 504 drugs were scored. Of those, 356 drugs were categorised as having no, 104 drugs were
scored as weak, 18 as moderate and 29 as having strong anticholinergic effects.
Conclusions: The newly created ACB score for drugs authorized in Germany can be used in daily clinical practice to
reduce potentially inappropriate medications for elderly patients. Further clinical studies investigating its effect
on reducing anticholinergic side effects are necessary for validation.
Keywords: Anticholinergic, Geriatrics, Anticholinergic scales, Anticholinergic burden, Germany, Expert opinion,
Potentially inappropriate medicine
Background
Studies show that over 50% of elderly patients take five
or more drugs, both prescription and over-the-counter
[1]. A cross-sectional study in Germany revealed further
that 62% of people aged 65 or older suffer from multi-
morbidity [2]. This combination of multimorbidity and
polypharmacy leads to a higher risk for drug-drug inter-
actions and adverse drug reactions (ADRs) [3, 4]. Hence,
the use of drugs should be considered carefully in geriat-
ric patients. Part of this consideration should be to avoid
potentially inappropriate medications.
Drugs with anticholinergic properties are part of in-
appropriate medications for geriatric patients [5, 6]. Anti-
cholinergic activity of multiple drugs add up to the
so-called anticholinergic burden (ACB). Older patients are
more prone to anticholinergic side effects than younger
patients [5, 6]. Due to reduced metabolic capacity and slo-
wed elimination in older patients, drugs are eliminated
slower, in addition to age-related reductions in cholinergic
transmissions [5, 6]. The permeability of the blood-brain-
barrier increases which leads to a higher drug concentra-
tion in the central nervous system [7]. Central nervous
ADRs may especially increase the risk of falls, e.g. blurred
vision, confusion, or tremors [6]. More severe anticholin-
ergic side effects are tachyarrhythmia, hallucinations, de-
lirium, and cognitive impairment [6]. Other ADRs like dry
mouth, constipation, and urinary retention might reduce
the quality of life [6]. Several reviews indicate a higher risk
for falls, cognitive decline and delirium with an increased
ACB of older patients [8–12].
Despite these apparent risks it is estimated that ap-
proximately 50% of elderly people take anticholinergic
medications [13, 14]. Qualitative studies demonstrated
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that very few prescribers are aware of the anticholinergic
properties of drugs and of the nature of anticholinergic
side effects [15]. Even if they know about the negative
impact of anticholinergic medications, they hesitate to
deprescribe or change those drugs as they do not feel re-
sponsible or lack time, knowledge, and resources [16]. In
clinical practice there is rarely a registration, documenta-
tion and/or conscious reduction of the ACB [15, 17].
Worldwide studies identified over 100 different drugs
as having anticholinergic properties [9, 10, 18–33]. De-
pending on study population, method, and setting, there
are different drug lists and different scales to calculate
the ACB [18, 19]. The variety of scales and systems com-
plicates the implementation in practice.
Therefore, the current study aimed to develop an anti-
cholinergic burden score specifically for the German
healthcare system. This, in turn, can help German pre-
scribers identify and reduce drugs with anticholinergic
properties in geriatric patients in order to facilitate easy
application in the daily clinical setting. To our knowledge
a specific ACB score for Germany is not yet available.
Methods
To identify appropriate tools, PubMed was searched for
systematic reviews on tools to quantify anticholinergic
drug burden. The search terms were “review AND anti-
cholinergic burden AND (scale OR list OR tool)” with-
out a date limitation. The search was conducted on
December 1, 2016. The search and identification process
is presented in Fig. 1. Articles were excluded if they were
not systematic reviews on tools to quantify anticholiner-
gic drug burden or the language was not English. Three
systematic reviews [11, 18, 34] were included identifying
12 tools to quantify anticholinergic burden [10, 20–26,
32, 33, 35, 36]. Tools were excluded because the scoring
system was not comparable to the other tools [33, 36],
the tool was outdated, [35] there was an updated version
published [32], or the scoring was solely based on serum
assays [25]. Literature reviews and meta-analysis failed
to show an association of serum anticholinergic activity
and anticholinergic effects [37], whereas there is an asso-
ciation shown for anticholinergic drug scores mainly
based on expert opinion [8–12, 27]. To avoid missing
relevant tools, the excluded articles were reviewed re-
garding more tools as they all evaluated the association
of anticholinergic drugs and negative outcomes in pa-
tients [9, 19, 27, 38, 39]. These reviews identified four
further tools, all ineligible for inclusion because (1) it
was impossible to access the drug list despite contacting
the authors [28, 31], (2) the scoring system was not
comparable to other drug lists [29], and (3) the study
assessed the overall medication of patients not specific
drugs [30]. The included anticholinergic drug lists were
summarized and reduced to drugs available in Germany
[10, 20–24, 26]. For Boustani et al. an updated version
was included [10, 40].
The approach to merge the identified scales was simi-
lar to the approach of Duran et al. [18]. For all scales,
quantitative grading scores proposed by the authors
were extracted. Most lists used scores ranging from 0 to
3, one was modified according to Duran et al. so that its
0–4 scale was comparable to 0–3 scales [18, 24]. Top-
ical, ophthalmic, otic and nasal drugs were excluded,
while oral, parenteral, inhalative and transdermal drugs
were included as these are more likely to show systemic
effects [41]. As these lists have only low to moderate
concordance, the algorithm depicted in Fig. 2 was used
to get a consistent scoring.
Where further evaluation was needed as existing lists
scored them differently or only one of the scores evalu-
ated that specific drug., one researcher (EK) looked at
the mechanism of action and the ADRs as reported in
the German Summary of Product Characteristics and
DRUGDEX® (expert-reviewed database for detailed drug
information) to assess the anticholinergic properties of
the respective drug. This assessment, the existing scores
and the scoring by Duran et al. [18] were discussed in a
multidisciplinary team of one geriatrician and two clin-
ical pharmacists. This discussion led to a final score.
Each drug was coded according to the Anatomical,
Fig. 1 Identification of tools
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Therapeutic and Chemical (ATC) Classification from the
World Health Organization. If there were discrepancies
in rating within the same drug class, we reconsidered
some ratings as well.
In order to tailor the ACB list to the clinical setting a
retrospective evaluation of admission and discharge
medication on an acute geriatric ward identified a range
of further drugs. Consecutive patients for two 6-week-
periods were included, which meant the admission and
discharge medication of 34 patients was evaluated. The
patients were prescribed a total of 235 drugs at admis-
sion and 276 drugs at discharge. All drugs thus identified
that were not mentioned in the reviewed scales were eval-
uated for their anticholinergic properties as described
above. Based on our final anticholinergic drug list, we de-
signed a pocket-sized guideline for prescribers with infor-
mation on anticholinergic drugs, anticholinergic side
effects and recommendations how to assess and handle
the ACB of patients on ward. The recommendation was
based on the approach of Boustani et al. and is presented
in Fig. 3 [10].
The anticholinergic scores of all drugs used by a pa-
tient were calculated in total. If one drug scored 3 or the
patient had a summated score of 3 or higher, it was rec-
ommended to switch to alternative drugs with a lesser
ACB score in order to reduce the summated score to < 3
[10]. If discontinuation or switching was not possible, a
dose reduction and/or monitoring for ADRs were ad-
vised. Through the upper limit of score 3, the suggested
ceiling effect of the ACB is included [19]. This means
that at a high ACB, drug effects are assumed to reach a
plateau even when the number of anticholinergic drugs
further increases [19].
Results
The summary of existing anticholinergic drug lists [20–
24, 26, 40] resulted in a list of 692 different drugs with
548 available in Germany (for excluded, international
drugs see Additional file 1: Table S1). In total, 67 drugs
were excluded because they were rated for topical, nasal,
ophthalmic, or otic application only, or were drug com-
binations (Additional file 1: Table S2).
In terms of effect, 334 of the drugs were categorised
as having no anticholinergic effects (ACB score = 0),
77 of the drugs were scored as displaying weak anti-
cholinergic effects (ACB score = 1), 10 as moderate
anticholinergic effects (ACB score = 2) and 27 as
strong anticholinergic effects (ACB score = 3). These
anticholinergic drugs are displayed in Table 1. Drugs
rated as having no anticholinergic effects are available
in the supplementary material.
Further evaluation was required for 35 drugs. After
consideration of adverse drug reactions and mechanism
of action, we scored one drug with no anticholinergic
effects (ACB score = 0), 22 drugs with weak anticholin-
ergic effects (ACB score = 1), eight as moderate anti-
cholinergic effects (ACB score = 2), and four as having
strong anticholinergic effects (ACB score = 3). See
Table 2 for specific drugs.
During the retrospective evaluation, 26 drugs were
identified that were not yet scored by these already exist-
ing scores. Parallel to drugs with inconsistent scores, the
adverse drug reactions and the mechanism of action
were reviewed and the drugs discussed by three re-
searchers to score the drugs. Five drugs were scored as
weak anticholinergic effects (ACB score = 1) and 21
Fig. 2 Algorithm for consistent scoring
Fig. 3 Recommendation for prescribers on pocket-card based on
Boustani et al. [10]
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Table 1 Anticholinergic drugs with concordant ratings of sores
Drug ATC-Code Carnahan 2006
USA [20]
Ancelin 2006
France [21]
Rudolph 2008
USA [22]
Han
2008
USA
[23]
Ehrt 2010 Norway
modified [24]
Sittironnarit 2011
Australia [26]
Boustani 2012
USA [40]
Duran 2013 [18]
Weak anticholinergic effects ACB score 1
Ampicillin J01CA01 1 0 or 1
Aripiprazole N05AX12 0 1
Atenolol C07AB03 0 1 0 0 1 0
Azathioprine L04AX01 1 0 or 1
Benazepril C09AA07 0 1 0 or 1
Betaxolol C07AB05 1 0 0 or 1
Bisacodyl A06AB02 0 1 0 or 1
Bromocriptine N04 BC01 1 0 weak(1–2)
Bupropion N06AX12 0 1 1 0 or 1
Captopril C09AA01 1 0 0 1 0 or 1
Celecoxib M01AH01 0 1 0 or 1
Chlordiazepoxide N05BA02 1 1 weak(1–2)
Chlorthalidone C03BA04 1 0 1 0 or 1
Ciclosporin L04 AD01 1 0 or 1
Citalopram N06AB04 0 1 1 weak(1–2)
Clindamycin J01FF01 1 0 or 1
Clonazepam N03AE01 1 1 weak(1–2)
Dexamethasone H02AB02 1 0 0 or 1
Dextromethorphan R05DA09 0 1 0 or 1
Diazepam N05BA01 1 1 1 1 1 weak(1–2)
Digitoxin C01AA04 1 1 weak(1–2)
Diltiazem C08DB01 1 0 0 or 1
Dipyridamole B01AC07 1 0 1 0 or 1
Domperidone A03FA03 1 weak(1–2)
Entacapone N04BX02 0 1 weak(1–2)
Escitalopram N06AB10 0 1 0 or 1
Famotidine A02BA03 1 0 0 or 1
Fentanyl N02AB03 1 1 weak(1–2)
Flunitrazepam N05CD03 1 0 or 1
Fluoxetine N06AB03 1 1 1 1 weak(1–2)
Flurazepam N05CD01 1 0 or 1
Fluvoxamine N06AB08 1 1 1 1 weak(1–2)
Gentamicin J01GB03 1 0 or 1
Guaifenesin R05CA03 0 1 0 or 1
Hydralazine C02DB02 1 0 1 0 or 1
Hydrocortisone H02AB09 1 1 0 or 1
Isosorbide dinitrate C01DA08 1 0 0 0 or 1
Isosorbide
mononitrate
C01DA14 1 0 0 or 1
Ketorolac M01AB15 1 weak(1–2)
Lansoprazole A02BC03 0 1 0 0 or 1
Levodopa N04BA01 0 1 1 0 0 or 1 0 or 1
Lithium N05AN01 0 1 weak(1–2)
Lorazepam N05BA06 1 0 or 1
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Table 1 Anticholinergic drugs with concordant ratings of sores (Continued)
Drug ATC-Code Carnahan 2006
USA [20]
Ancelin 2006
France [21]
Rudolph 2008
USA [22]
Han
2008
USA
[23]
Ehrt 2010 Norway
modified [24]
Sittironnarit 2011
Australia [26]
Boustani 2012
USA [40]
Duran 2013 [18]
Metformin A10BA02 0 1 0 or 1
Methotrexate L04AX03 0 1 0 or 1
Methylprednisolone H02AB04 1 0 0 or 1
Metoprolol C07AB02 0 1 0 0 1 0
Midazolam N05CD08 1 0 or 1
Mirtazapine N06AX11 0 1 weak(1–2)
Morphine N02AA01 1 1 1 weak(1–2)
Naratriptan N02CC02 1 0 or 1
Nifedipine C08CA05 1 0 0 1 0
Oxazepam N05BA04 1 0 1 0 or 1
Oxycodone N02AA05 1 1 1 weak(1–2)
Pancuronium M03 AC01 1 0 or 1
Phenobarbital N03AA02 0 1 1 0 or 1
Piperacillin J01CA12 1 0 or 1
Pramipexole N04 BC05 0 1 0 0 or 1
Prednisolone A07EA01 1 0 0 0 or 1
Prednisone A07EA03 1 1
Quinidine C01BA01 0 1
Risperidone N05AX08 0 1 1 1 1 weak(1–2)
Selegiline N04BD01 0 1 0 0 or 1
Sertraline N06AB06 1 1 0 0 0
Sumatriptan N02CC01 1 0 or 1
Temazepam N05CD07 1 1 weak(1–2)
Trandolapril C09AA10 0 1 0 0 or 1
Trazodone N06AX05 0 1 1 1 weak(1–2)
Triamcinolone H02AB08 1 0 0 or 1
Triamterene C03DB02 1 0 1 0 or 1
Triazolam N05CD05 1 1 weak(1–2)
Valproic acid N03AG01 1 0 0 or 1
Vancomycin J01XA01 1 0 or 1
Venlafaxine N06AX16 0 1 0 1 1 0
Warfarin B01AA03 1 0 0 1 0
Ziprasidone N05AE04 1 0 or 1
Zolmitriptan N02CC03 1 0 or 1
Moderate anticholinergic effects ACB score 2
Amantadine N04BB01 1 2 2 weak(1–2)
Cimetidine A02BA01 2 2 1 weak(1–2)
Loperamide A07DA03 1 2 1 1 1 weak(1–2)
Loxapine N05AH01 2 2 weak(1–2)
Methadone N07 BC02 2 weak(1–2)
Oxcarbazepine N03AF02 2 2 weak(1–2)
Pimozide N05AG02 2 2 weak(1–2)
Ranitidine A02BA02 2 1 2 1 1 1 weak(1–2)
Theophylline R03DA04 1 2 1 2 1 weak(1–2)
Tramadol N02AX02 1 2 2 weak(1–2)
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drugs were categorised as having no anticholinergic ef-
fects (ACB score = 0). See Table 3 for specific drugs.
Table 4 shows all drugs scored sorted by their score.
Additional file 1: Table S3 shows all drugs scored 0.
Discussion
To our knowledge, this is the first ACB score developed
especially for prescribers in Germany. There have been
similar international publications [18, 27]. The drugs
most commonly used in Germany differ from other
countries especially England, USA, and Australia, where
many published studies on anticholinergic drugs were
conducted. Our ACB score did not only summarize
existing scores but re-evaluated the drugs, especially
those with discrepancies, and reduced the list to those
authorized in Germany. This saves valuable time and ef-
fort for clinicians trying to evaluate anticholinergic bur-
den in patients.
The scores used were identified via a systematic lit-
erature search in pubmed. This systematic approach
should ensure a replicable and complete choice of
peer-reviewed and published ACB scores, although it
was not a systematic literature review conducted in dif-
ferent databases. All included scores were previously
validated. Drug evaluation was based on expert opinion
which was previously preferred to measuring serum as-
says [18, 27]. This expert review of the drugs by three
different people (one geriatrician and two clinical phar-
macists) based on clinical experience and literature data
on method of action and ADRs strengthens the devel-
opment of this score. Scoring was confirmed by the ex-
pert committee not only for drugs with discrepancies,
but also for drugs that were only scored by one of the
existing scores. Being rated by only one score is not ne-
cessarily a limitation as the individual selection of drugs
is always depending on the country, the setting, and
other specifics of the score development.
Table 1 Anticholinergic drugs with concordant ratings of sores (Continued)
Drug ATC-Code Carnahan 2006
USA [20]
Ancelin 2006
France [21]
Rudolph 2008
USA [22]
Han
2008
USA
[23]
Ehrt 2010 Norway
modified [24]
Sittironnarit 2011
Australia [26]
Boustani 2012
USA [40]
Duran 2013 [18]
Strong anticholinergic effects ACB score 3
Amitriptyline N06AA09 3 3 3 3 3 3 3 Strong(3)
Atropine A03BA01 3 3 3 3 3 Strong(3)
Chlorpheniramine R06AB04 3 3 3 3 3 3 Strong(3)
Clemastine R06AA04 3 3 Strong(3)
Clomipramine N06AA04 3 3 3 Strong(3)
Clozapine N05AH02 3 2 3 3 Strong(3)
Cyproheptadine R06AX02 2 3 3 2 Strong(3)
Darifenacin G04BD10 3 3 Strong(3)
Dimenhydrinate A04AB02 3 3 Strong(3)
Diphenhydramine A04AB05 3 3 3 3 Strong(3)
Doxepin N06AA12 3 3 3 3 3 Strong(3)
Flavoxate G04BD02 3 3 Strong(3)
Hydroxyzine N05BB01 3 3 3 3 Strong(3)
Imipramine N06AA02 3 3 3 3 3 3 Strong(3)
Levomepromazine N05AA02 2 3 2 Strong(3)
Nortriptyline N06AA10 3 2 3 2 3 Strong(3)
Orphenadrine N04AB02 3 3 3 3 Strong(3)
Oxybutynin G04BD04 3 3 3 3 2 3 Strong(3)
Procyclidine N04AA04 3 Strong(3)
Scopolamine A04AD01 3 3 3 Strong(3)
Thioridazine N05 AC02 3 3 3 3 3 Strong(3)
Tizanidine M03BX02 3 Strong(3)
Tolterodine G04BD07 3 2 3 3 3 Strong(3)
Trihexyphenidyl N04AA01 3 3 3 3 3 Strong(3)
Trimipramine N06AA06 3 3 3 3 Strong(3)
Drugs are sorted by their assigned score and then alphabetical
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As our score is based on previously published ACB
scores and drugs within our hospital during a retrospect-
ive evaluation, we do not claim this list to be comprehen-
sive. There are over 2000 drugs approved in Germany, so
there are potentially more anticholinergic drugs not yet
considered in this list. There were few drugs found in our
retrospective evaluation that had not been rated by previ-
ously published ACB scores. Potential reasons for those
Table 2 Scoring of drugs with discrepant ratings (=ratings differed more than 1 score) or only one previous scoring
Drug ATC-Code Carnahan 2006
USA [20]
Ancelin 2006
France [21]
Rudolph 2008
USA [22]
Han 2008
USA [23]
Ehrt 2010 Norway
modified [24]
Sittironnarit 2011
Australia [26]
Boustani 2012
USA [40]
Duran 2013 [18]
No anticholinergic effects ACB score 0
Colchicine M04 AC01 0 3 0 1 discrepant
Weak anticholinergic effects ACB score 1
Alprazolam N05BA12 1 3 1 1 1 discrepant
Asenapine N05AH05 1
Baclofen M03BX01 0 2 2 1 or 2
Cetirizine R06AE07 0 2 2 2 1 1 or 2
Clorazepate N05BA05 1 3 1 discrepant
Codeine R05DA04 1 2 1 0 1 1 1 or 2
Desloratadine R06AX27 1
Digoxin C01AA05 1 3 1 1 1 discrepant
Doxylamine R06AA09 0 3
Fexofenadine R06AX26 0 2 2 0 1 or 2
Fluphenazine N05AB02 1 3 3 3
Furosemide C03CA01 1 3 1 0 1 discrepant
Ipratropium
inhalative
R03BB01 0 3 3
Levocetirizine R06AE09 1
Loratadine R06AX13 0 2 1 1 1 1 or 2
Methocarbamol M03BA03 1 1 3 1 or 2
Metoclopramide A03FA01 0 1 3 0 1 discrepant
Paliperidone N05AX13 1
Perphenazine N05AB03 1 3 2 0 3 discrepant
Promethazine R06AD02 3 3 0 3 3
Pseudoephedrine R01BA02 0 2 0 oder 1
Tiotropium
inhalative
R03BB04 0
Moderate anticholinergic effects ACB score 2
Carbamazepine N03AF01 2 1 0 0 2 1 or 2
Haloperidol N05 AD01 0 1 0 2 1 1 or 2
Maprotiline N06AA21 3 discrepant
Pethidine N02AB02 2 0 2 1 or 2
Olanzapine N05AH03 1 2 1 2 3 1 or 2
Opipramol N06AA05 3 discrepant
Paroxetine N06AB05 1 1 2 2 2 3 1 or 2
Quetiapine N05AH04 0 1 2 1 3 1 or 2
Strong anticholinergic effects ACB score 3
Fesoterodine G04BD11 3
Propiverine G04BD06 3
Solifenacin G04BD08 0 3
Trospium G04BD09 3
Drugs are sorted first by their assigned score and then alphabetical
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drugs missing could be that the drugs were mainly used in
Germany and not internationally, e.g. Metamizol sodium,
or that the drugs were new on the market and not previ-
ously analysed, e.g. Apixaban. To address missing and po-
tentially new anticholinergic drugs, updates are planned in
follow-up projects.
The validity of selection of drugs with anticholinergic
activity and the grading can be questioned. Among the
selected scores there is a great variety in study design
and setting. Different methods to assess and rate anti-
cholinergic activity were used: product information, spe-
cialised literature on ADRs, review of literature, expert
opinion as well as serum radio receptor assay, dissoci-
ation constant for cholinergic receptor and other labora-
tory data [10, 18–24, 26, 40]. We worked with that
variety by comparing different scores. As final decision
on inclusion and rating of anticholinergic drugs was
mainly a subjective decision of experts and not based on
clinical outcomes, the ratings may be discussed further.
Nevertheless, there is no approved methodology to
measure the ACB and expert rating is preferred to meas-
uring serum assays [27]. The list did not include topical,
ophthalmic, otic or nasal drugs. It cannot be excluded
that there might be systemic or local anticholinergic ef-
fects with these application routes.
The distinction of anticholinergic potency from 0 to 3
might not be the best method to quantify anticholinergic
burden, but as most existing scores used this or a similar
rating it was the only way to work with the existing lists
[18, 19]. Through the upper limit of score 3, the sug-
gested ceiling effect of the ACB was included [19]. This
means that at a high ACB, drug effects are assumed to
reach a plateau even when the number of anticholinergic
drugs further increases [19]. For a more accurate evalu-
ation of anticholinergic burden a finer distinction in
some drug classes would be useful. Drug classes like tri-
cyclic antidepressants or anticholinergics for urinary in-
continence were all scored with a strong ACB (ACB = 3).
Although those drugs all have a strong anticholinergic
burden, some are more problematic than others. For ex-
ample, Trospium should have less central reactions than
other anticholinergics for urinary incontinence because
of its quaternary chemical structure, but it still shows
anticholinergic adverse effects and was rated having
strong anticholinergic properties by Boustani et al. [40].
Another method to further refine the evaluation of ACB
would be to consider the dosages of anticholinergic
drugs via the Drug Burden Index [33]. A recently pub-
lished cohort study of German older outpatients found a
significant association of the drug Burden Index with
Mini-Mental State Examination Score, Barthel index,
Falls and use of laxatives [42]. We did not use this ap-
proach as it is more complicated and time-consuming to
use in daily routine and it is not compatible with the
scores used [11]. Our decision to apply the higher score
(Fig. 2 step 3) might be questioned due to the automatic
application of a higher anticholinergic rating. We de-
cided to take this approach in order to avoid missing
any drugs with anticholinergic properties.
Although a high anticholinergic burden should be
avoided if possible, the deprescribing of anticholinergic
drugs is not always possible. Some indications like for
example urinary incontinence or some psychiatric indi-
cations require anticholinergic medications that cannot
be easily subsidised by other non-anticholinergic drugs
due to clinical reasons. While urinary incontinence can
be handled well with non-pharmacological options, if
pharmacological treatment is required anticholinergic
drugs are the best options. Thus, this list should be
considered as decision support for the prescriber rather
than as a strict deprescribing directive.
Table 3 Drugs added during retrospective evaluation
Drug ATC-Code
No anticholinergic effects ACB score 0
Agomelatine N06AX22
Apixaban B01FAF02
Colecalciferol A11CC05
Dabigatran B01AE07
Dulaglutide A10BJ05
Edoxaban B01AF03
Empagliflozin A10BK03
Fenoterol inhalative R03AC04
Formoterol inhalative R03AC13
Metamizole N02BB02
Saccharomyces boulardii A07FA02
Phenprocoumon B01AA04
Pipamperone N05 AD05
Piritramide N02 AC03
Rivaroxaban B01AF01
Sevelamer V03AE02
Sitagliptin A10BH01
Teriparatide H05AA02
Thiamazole H03BB02
Tilidine/Naloxone N02AX51
Vemurafenib L01XE15
Weak anticholinergic effects ACB score 1
Aclidinium inhalative R03BB05
Dimetindene R06AB03
Etoricoxib M01AH05
Glycopyrronium inhalative R03BB06
Rotigotine patch N04 BC09
Drugs are sorted by their assigned score and then alphabetical
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Conclusion
Although anticholinergic burden is only one factor of
many to consider in multimorbid geriatric patients, it is
important to discuss anticholinergic burden and its ef-
fects. This list can be used in Germany and countries
with similar drugs approved to assess the anticholinergic
burden of geriatric patients. It is valuable for prescribers
to use in the daily clinical setting as only drugs available
in Germany are listed and data from different studies is
merged into one table so that a quick overview is pos-
sible. Further cluster-randomised studies investigating
whether the implementation of the list reduces anti-
cholinergic side effects, falls or delirium are necessary
for its validation.
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Table 4 Overview of all drugs scored. Caution: This list does not contain necessarily all drugs with anticholinergic properties
ACB score = 1 ACB score = 2 ACB score = 3
Aclidiniuminh
Alprazolam
Ampicillin
Aripiprazole
Asenapine
Atenolol
Azathioprine
Baclofen
Benazepril
Betaxolol
Bisacodyl
Bromocriptine
Bupropion
Captopril
Celecoxib
Cetirizine
Chlordiazepoxide
Chlorthalidone
Ciclosporin
Citalopram
Clindamycin
Clonazepam
Clorazepate
Codeine
Desloratadine
Dexamethasone
Dextromethorphan
Diazepam
Digitoxin
Digoxin
Diltiazem
Dimetindene
Dipyridamole
Domperidone
Doxylamine
Entacapone
Escitalopram
Etoricoxib
Famotidine
Fentanyl
Fexofenadine
Flunitrazepam
Fluoxetine
Fluphenazine
Flurazepam
Fluvoxamine
Furosemide
Gentamicin
Glycopyrroniuminh
Guaifenesin
Hydralazine
Hydrocortisone
Ipratropiuminh
Isosorbide dinitrate
Isosorbide mononitrate
Ketorolac
Lansoprazole
Levocetirizine
Levodopa
Lithium
Loratadine
Lorazepam
Metformin
Methocarbamol
Methotrexate
Methylprednisolone
Metoclopramide
Metoprolol
Midazolam
Mirtazapine
Morphine
Naratriptan
Nifedipine
Oxazepam
Oxycodone
Paliperidone
Pancuronium
Perphenazine
Phenobarbital
Piperacillin
Pramipexole
Prednisolone
Prednisone
Promethazine
Pseudoephedrine
Quinidine
Risperidone
Rotigotine patch
Selegiline
Sertraline
Sumatriptan
Temazepam
Tiotropiuminh
Trandolapril
Trazodone
Triamcinolone
Triamterene
Triazolam
Valproic acid
Vancomycin
Venlafaxine
Warfarin
Ziprasidone
Zolmitriptan
Amantadine
Carbamazepine
Cimetidine
Haloperidol
Loperamide
Loxapine
Maprotiline
Methadone
Olanzapine
Opipramol
Oxcarbazepine
Paroxetine
Pethidine
Pimozide
Quetiapine
Ranitidine
Theophylline
Tramadol
Amitriptyline
Atropine
Chlorpheniramine
Clemastine
Clomipramine
Clozapine
Cyproheptadine
Darifenacin
Dimenhydrinate
Diphenhydramine
Doxepin
Fesoterodine
Flavoxate
Hydroxyzine
Imipramine
Levomepromazine
Nortriptyline
Orphenadrine
Oxybutynin
Procyclidine
Propiverine
Scopolamine
Solifenacin
Thioridazine
Tizanidine
Tolterodine
Trihexyphenidyl
Trimipramine
Trospium
inhinhalative
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